Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).

Saved in:
Bibliographic Details
Title: Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Authors: Pathmanandavel S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Crumbaker M; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Ho B; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Yam AO; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Wilson P; MIM Software, Inc., Cleveland, Ohio., Niman R; MIM Software, Inc., Cleveland, Ohio., Ayers M; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Sharma S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Hickey A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Eu P; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and., Stockler M; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Joshua AM; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Emmett L; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia; louise.emmett@svha.org.au.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Feb; Vol. 64 (2), pp. 221-226. Date of Electronic Publication: 2022 Aug 25.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1535-5667
DOI:10.2967/jnumed.122.264398